<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Calcitriol (systemic): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Calcitriol (systemic): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Calcitriol (systemic): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="107356" href="/d/html/107356.html" rel="external">see "Calcitriol (systemic): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="107355" href="/d/html/107355.html" rel="external">see "Calcitriol (systemic): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F28561742"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Rocaltrol</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871946"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Calcitriol-Odan;</li>
<li>Rocaltrol;</li>
<li>TARO-Calcitriol</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F28561748"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Vitamin D Analog</li></ul></div>
<div class="block doa drugH1Div" id="F28561796"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c2769f1d-1cc5-4907-9b6b-2546d31d657f">Hypocalcemia associated with hypoparathyroidism/pseudohypoparathyroidism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypocalcemia associated with hypoparathyroidism/pseudohypoparathyroidism:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 0.25 to 0.5 mcg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goltzman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goltzman.1'])">Ref</a></span>). May adjust dose in 0.25 mcg/day increments every 1 to 4 weeks if needed to achieve target albumin-corrected serum calcium levels; usual dosage range: 0.5 to 2 mcg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26943719','lexi-content-ref-Goltzman.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26943719','lexi-content-ref-Goltzman.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients discontinuing recombinant parathyroid hormone (rPTH) therapy:</i> Increased doses of calcitriol and supplemental calcium may be required to prevent severe acute hypocalcemia, especially if rPTH therapy is discontinued abruptly. Resume pre-rPTH treatment doses of calcitriol and calcium supplementation within 12 hours of discontinuation, with close monitoring of serum calcium (eg, every 3 days); some patients may require calcium and calcitriol doses up to 2 to 3 times the pre-rPTH treatment doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26943719','lexi-content-ref-31042826','lexi-content-ref-Goltzman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26943719','lexi-content-ref-31042826','lexi-content-ref-Goltzman.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="34a2d0ce-62ae-4cb6-9568-e0e2d820060d">Hypophosphatemia, X-linked</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypophosphatemia, X-linked (ie, vitamin D-resistant rickets) (off-label use):</b>
<b>Oral:</b> Initial: 0.5 to 0.75 mcg/day in 2 divided doses; after 4 to 6 weeks, assess biochemical response; dose may be adjusted upward or downward in increments of 0.25 mcg/day every 3 to 4 weeks to maintain normal serum parathyroid hormone (PTH) and calcium while avoiding hypercalciuria. Consider discontinuing therapy if clinical improvement is not observed within 9 to 12 months. <b>Note:</b> Calcitriol may be initiated ~1 week prior to initiating phosphate therapy to reduce the risk of exacerbating preexisting secondary hyperparathyroidism or causing it to develop (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21538511']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21538511'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3420800a-bbc4-4b1f-995a-9cb4b201dd43">Secondary hyperparathyroidism in chronic kidney disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Secondary hyperparathyroidism in chronic kidney disease: Note:</b> Kidney Disease: Improving Global Outcomes (KDIGO) guidelines do not recommend routine use of calcitriol or other vitamin D analogs in patients with chronic kidney disease (CKD) stages G3 to G5; it may be reasonable to reserve use for patients with CKD stages G4 or G5 and with severe and progressive hyperparathyroidism. Caution is advised to avoid hypercalcemia or elevated phosphate levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30675420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30675420'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients on dialysis:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: 0.25 mcg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>); some experts recommend more conservative initial doses (eg, 0.25 mcg 3 times <b>weekly</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Quarles.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Quarles.1'])">Ref</a></span>); may increase dose by 0.25 mcg/day at 4- to 8-week intervals, up to 0.5 to 1 mcg/day. Patients with normal or mildly decreased serum calcium levels may respond to 0.25 mcg every other day.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> Initiate carefully; 0.5 mcg 3 times<b> weekly</b> is the lowest recommended dose in the manufacturer’s labeling; some experts recommend more conservative initial doses (eg, 0.25 mcg 3 times <b>weekly</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Quarles.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Quarles.1'])">Ref</a></span>). Adjust dose by 0.5 to 1 mcg at 2- to 4-week intervals; dosing range: 0.5 to 4 mcg 3 times <b>weekly</b>. Gradual dose reduction and discontinuation of therapy may be necessary as PTH levels decrease in response to therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients with moderate to severe chronic kidney disease not yet on dialysis:</i>
<b>Note:</b> The magnitude of PTH response is highly variable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22285224']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22285224'])">Ref</a></span>). KDIGO guidelines recommend initiating with low doses independent of initial PTH concentration and then titrating based on PTH response while avoiding hypercalcemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30675420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30675420'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: 0.25 mcg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>); some experts recommend more conservative initial doses (eg, 0.25 mcg 3 to 4 times <b>weekly</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Quarles.2','lexi-content-ref-22285224']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Quarles.2','lexi-content-ref-22285224'])">Ref</a></span>); may increase to 0.5 mcg/day if needed.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="343416f5-37ea-462d-bff2-235b6cf15d4f">Vitamin D-dependent rickets type 1/pseudovitamin D deficiency rickets</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vitamin D-dependent rickets type 1/pseudovitamin D deficiency rickets (PDDR) (off-label use):</b>
<b>Oral:</b> Initial: 0.5 mcg twice daily; subsequent dosing adjusted to maintain normal serum calcium and PTH levels; median dose after 2 years: 0.25 mcg daily (range: 0.1 to 0.5 mcg daily) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20926527']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20926527'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Discontinuation of therapy for hypercalcemia:</b></i> Discontinue therapy if hypercalcemia occurs; monitor calcium and phosphorous daily until levels normalize. Upon normalization, treatment with calcitriol can be resumed, at a reduced dose than that previously used. Assess dietary calcium intake and adjust if indicated.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991073"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment likely to be necessary for any degree of kidney dysfunction (primarily excreted in feces) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be significantly dialyzed (highly protein bound) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9335388','lexi-content-ref-12358640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9335388','lexi-content-ref-12358640'])">Ref</a></span>): No supplemental dose or dosage adjustment likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed (highly protein bound) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12358640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12358640'])">Ref</a></span>): No dosage adjustment likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988339"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;text-align:justify;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F28561797"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. Start at the lower end of the dosage range.</p></div>
<div class="block dop drugH1Div" id="F28561795"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="107355" href="/d/html/107355.html" rel="external">see "Calcitriol (systemic): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9d5dbbc1-7bcb-4c78-a14e-55844fc448e4">Chronic kidney disease-mineral and bone disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic kidney disease-mineral and bone disorder (CKD-MBD):</b> Limited data available: <b>Note:</b> In pediatric patients with CKD stages 3a through 5 with elevated parathyroid hormone (PTH), guidelines recommend consideration of calcitriol use to maintain serum calcium in age-appropriate normal range; optimal serum PTH concentration remains undefined (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30675420','lexi-content-ref-28941764']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30675420','lexi-content-ref-28941764'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CKD stages 3a to 4</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Dosing recommendations based on the 2005 KDOQI Guidelines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDOQI.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDOQI.1'])">Ref</a></span>). Dosage should be adjusted based on patient response (eg, calcium, phosphorus, PTH levels).</p>
<p style="text-indent:-2em;margin-left:8em;">Initial dose:</p>
<p style="text-indent:-2em;margin-left:10em;">&lt;10 kg: Oral: 0.05 mcg every other day.</p>
<p style="text-indent:-2em;margin-left:10em;">10 to 20 kg: Oral: 0.1 to 0.15 mcg once daily.</p>
<p style="text-indent:-2em;margin-left:10em;">&gt;20 kg: Oral: 0.25 mcg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">Dosage adjustment:</p>
<p style="text-indent:-2em;margin-left:10em;">If intact parathyroid hormone (iPTH) decrease is &lt;30% after 3 months of therapy and serum levels of calcium and phosphorus are within the target ranges based upon the CKD stage, increase dosage by 50%.</p>
<p style="text-indent:-2em;margin-left:10em;">If iPTH decreases to &lt; target range for CKD stage, hold calcitriol therapy until iPTH increases to above target range; resume therapy at half the previous dosage (if dosage &lt;0.25 mcg capsule or 0.05 mcg liquid, use every other day therapy).</p>
<p style="text-indent:-2em;margin-left:10em;">If serum levels of total corrected calcium exceed 10.2 mg/dL, hold calcitriol therapy until serum calcium decreases to &lt;9.8 mg/dL; resume therapy at half the previous dosage (if dosage &lt;0.25 mcg capsule or 0.05 mcg liquid, use every other day therapy).</p>
<p style="text-indent:-2em;margin-left:10em;">If serum levels of phosphorus increase to &gt; age-appropriate upper limits, hold calcitriol therapy; resume therapy at half the previous dosage.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CKD stage 5 requiring dialysis</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Dosing recommendations based on the 2005 KDOQI Guidelines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDOQI.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDOQI.1'])">Ref</a></span>). Dosage should be adjusted based on patient response (eg, calcium, phosphorus, PTH levels) and concomitant therapies; to ensure adequate bone health in children, maintain calcium in normal range; avoid hypocalcemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28941764']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28941764'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Initial dose:</p>
<p style="text-indent:-2em;margin-left:10em;">iPTH 300 to 500 pg/mL: Oral, IV: 0.0075 mcg/<b>kg</b> 3 times weekly; maximum dose: 0.25 mcg/dose.</p>
<p style="text-indent:-2em;margin-left:10em;">iPTH &gt;500 to 1,000 pg/mL: Oral, IV: 0.015 mcg/<b>kg</b> 3 times weekly; maximum dose: 0.5 mcg/dose.</p>
<p style="text-indent:-2em;margin-left:10em;">iPTH &gt;1,000 pg/mL: Oral, IV: 0.025 mcg/<b>kg</b> 3 times weekly; maximum dose: 1 mcg/dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Dosage adjustment: If iPTH decrease is &lt;30% after 3 months of therapy and serum levels of calcium and phosphorus are within the target ranges for CKD stage 5, increase dosage by 50%.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="abb46306-65a4-49b0-a12d-b98f68036aa0">Hypoparathyroidism/pseudohypoparathyroidism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypoparathyroidism/pseudohypoparathyroidism:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Dosage should be adjusted based on patient response.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: Limited data available: Oral: 0.02 to 0.06 mcg/<b>kg</b> once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Root.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Root.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 1 to 5 years: Oral: 0.25 to 0.75 mcg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents: Oral: 0.5 to 2 mcg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="20140961-21de-446c-86c8-221a7fa904e7">Vitamin D-dependent rickets</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vitamin D-dependent rickets:</b> Infants, Children, and Adolescents: Oral: Initial: 0.25 to 2 mcg once daily; adjust dose based on clinical response to maintain low-normal serum calcium level, normal serum phosphorus level, and a high-normal serum PTH level; reduce dose once rickets has healed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Greenbaum.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Greenbaum.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51083757"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block dohp drugH1Div" id="F51083758"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F28561765"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Endocrine &amp; metabolic: Hypercalcemia</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Polydipsia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia, hypertension</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Apathy, drowsiness, hyperthermia, metallic taste, psychosis, sensory disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema, erythema multiforme, pruritus, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Albuminuria, calcinosis, decreased libido, dehydration, growth suppression, hypercholesterolemia, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, constipation, pancreatitis, stomach pain, vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hypercalciuria, nocturia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum ALT, increased serum AST</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Pain at injection site (mild)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Dystrophy, myalgia, ostealgia, weakness</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis, photophobia</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Calcium nephrolithiasis, increased blood urea nitrogen, increased serum creatinine, polyuria</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Rhinorrhea</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing and/or case reports: Agitation, anaphylaxis, apprehension, hypermagnesemia, hyperphosphatemia, hypervitaminosis D, increased hematocrit, increased hemoglobin, increased neutrophils, increased serum alkaline phosphatase, insomnia, limb pain, lymphocytosis</p></div>
<div class="block coi drugH1Div" id="F28561762"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to calcitriol, other vitamin D analogues, or any component of the formulation; hypercalcemia, vitamin D toxicity</p></div>
<div class="block war drugH1Div" id="F28561763"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Excessive vitamin D: Excessive vitamin D administration may lead to over suppression of parathyroid hormone (PTH), progressive or acute hypercalcemia, hypercalciuria, hyperphosphatemia and adynamic bone disease. Withhold pharmacologic doses of vitamin D and its derivatives during therapy to avoid the potential for hypercalcemia to develop. In addition, several months may be required for ergocalciferol levels to return to baseline in patients switching from ergocalciferol therapy to calcitriol.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypercalcemia: Monitor calcium levels closely with initiation of therapy and with dose adjustments; discontinue use promptly in patients who develop hypercalcemia. Avoid abrupt dietary modifications (eg, increased intake of dairy products) which may lead to hypercalcemia; adjust calcium intake if indicated and maintain adequate hydration. Chronic hypercalcemia can result in generalized vascular and soft tissue calcification, exacerbate nephrolithiasis, and has been associated with increased mortality in adults with chronic kidney disease (CKD) (KDIGO 2017). Immobilized patients may be at a higher risk for hypercalcemia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Malabsorption syndrome: Use oral calcitriol with caution in patients with malabsorption syndromes; efficacy may be limited and/or response may be unpredictable.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Calcitriol can increase serum phosphate levels in patients with kidney impairment. Progressive or persistently increased serum phosphate levels in patients with CKD stage G3a to G5D may lead to ectopic calcification; phosphate-lowering treatment (eg, low phosphate diet alone or in combination with phosphate binders and/or dialysis) may be necessary (KDIGO 2017).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register 2002). See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Coconut oil: Products may contain coconut oil (capsule).</p>
<p style="text-indent:-2em;margin-left:4em;">• Palm seed oil: Products may contain palm seed oil (oral solution).</p>
<p style="text-indent:-2em;margin-left:4em;">• Tartrazine: Some products may contain tartrazine.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Calcium: Adequate dietary (supplemental) calcium is necessary for clinical response to vitamin D. Patients with a tendency to develop hypercalcemia may require low doses of calcium or no supplementation at all.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878802"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Calcium, phosphorus, and parathyroid hormone levels should be monitored closely and the calcitriol dosage adjusted accordingly. The combination of hypercalcemia and hyperphosphatemia may result in adverse outcomes such as soft tissue or vascular calcification (KDOQI 2005; KDIGO 2017). Previously, expert opinion was that serum calcium times phosphorus product (Ca × P) should not exceed 65 mg<sup>2</sup>/dL<sup>2</sup> for infants and children and 55 mg<sup>2</sup>/dL<sup>2</sup> for adolescents (KDOQI 2005). Current guidelines do not recommend use of the calcium phosphorus product, but rather suggest that calcium and phosphorus values should be considered individually/evaluated together, with age-appropriate normal values targeted (KDIGO 2017).</p></div>
<div class="block foc drugH1Div" id="F28561814"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rocaltrol: 0.25 mcg, 0.5 mcg [contains fd&amp;c yellow #6 (sunset yellow), methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.25 mcg, 0.5 mcg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mcg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rocaltrol: 1 mcg/mL (15 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mcg/mL (15 mL)</p></div>
<div class="block geq drugH1Div" id="F28561746"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F28561819"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Calcitriol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25 mcg (per each): $0.33 - $1.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mcg (per each): $0.51 - $2.50</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Rocaltrol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25 mcg (per each): $2.05</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mcg (per each): $3.22</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Calcitriol Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mcg/mL (per mL): $11.94</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Calcitriol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mcg/mL (per mL): $11.93 - $31.73</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Rocaltrol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mcg/mL (per mL): $17.17</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871947"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rocaltrol: 0.25 mcg, 0.5 mcg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.25 mcg, 0.5 mcg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mcg/mL (1 mL)</p></div>
<div class="block adm drugH1Div" id="F28561801"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IV: May be administered as a bolus dose IV through the catheter at the end of hemodialysis.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: May be administered without regard to food. Administer with meals to reduce GI problems.</p></div>
<div class="block admp drugH1Div" id="F52614600"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May be administered with or without meals.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: May be administered undiluted as a bolus dose IV through the hemodialysis catheter at the end of hemodialysis.</p></div>
<div class="block use drugH1Div" id="F28561752"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypocalcemia associated with hypoparathyroidism/pseudohypoparathyroidism:</b> Management of hypocalcemia in patients with hypoparathyroidism or pseudohypoparathyroidism (oral).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Secondary hyperparathyroidism in patients with chronic kidney disease:</b> Management of secondary hyperparathyroidism in patients with moderate to severe chronic kidney disease not on dialysis (oral) or in patients on dialysis (oral or IV). <b>Note:</b> Although the manufacturer’s labeling states that calcitriol may be used specifically to treat hypocalcemia in dialysis patients, due to the risk of hypercalcemia, use should generally be reserved for patients with severe and progressive hyperparathyroidism (KDIGO 2017).</p></div>
<div class="block off-label drugH1Div" id="F28561753"><span class="drugH1">Use: Off-Label: Adult</span><p>Hypophosphatemia, X-linked (ie, vitamin D-resistant rickets); Vitamin D-dependent rickets type I/pseudovitamin D deficiency rickets (PDDR)</p></div>
<div class="block mst drugH1Div" id="F28561739"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Calcitriol may be confused with alfacalcidol, calcifediol, Calciferol, calcitonin, calcium carbonate, captopril, colestipol, paricalcitol, ropinirole</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Dosage is expressed in mcg (micrograms), <b>not</b> mg (milligrams); rare cases of acute overdose have been reported</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F28561772"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F28561769"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aluminum Hydroxide: Vitamin D Analogs may increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations.  Management: Consider avoiding chronic use of aluminum and aluminum-containing products in patients who are also taking active vitamin D analogs. If coadministered, monitor aluminum status and for signs and symptoms of aluminum-related toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (eg, cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Burosumab: Vitamin D Analogs may enhance the adverse/toxic effect of Burosumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Salts: May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Vitamin D Analogs may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May diminish the therapeutic effect of Calcitriol (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Calcitriol (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Calcitriol (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Danazol: May enhance the hypercalcemic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: Serum Phosphate Level-Altering Agents may diminish the therapeutic effect of Erdafitinib.  Management: Avoid coadministration of serum phosphate level-altering agents with erdafitinib before initial dose increase period based on serum phosphate levels (Days 14 to 21).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Salts: Calcitriol (Systemic) may increase the serum concentration of Magnesium Salts.  Management: Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving calcitriol. If magnesium-containing products must be used with calcitriol, serum magnesium concentrations should be monitored closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mineral Oil: May decrease the serum concentration of Vitamin D Analogs. More specifically, mineral oil may interfere with the absorption of Vitamin D Analogs. Management: Avoid concomitant, oral administration of mineral oil and vitamin D analogs. Consider separating the administration of these agents by several hours to minimize the risk of interaction. Monitor plasma calcium concentrations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the absorption of Vitamins (Fat Soluble). Management: Administer oral fat soluble vitamins at least 2 hours before or 2 hours after the administration of orlistat. Avoid concomitant administration due to the risk of impaired vitamin absorption.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sevelamer: May decrease the serum concentration of Calcitriol (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sucralfate: Vitamin D Analogs may increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration.  Management: Consider avoiding chronic use of aluminum and aluminum-containing products, such as sucralfate, in patients who are also taking active vitamin D analogs. If combined, monitor for signs and symptoms of aluminum-related toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May enhance the hypercalcemic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin D Analogs: May enhance the adverse/toxic effect of other Vitamin D Analogs.<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F28561758"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Maternal calcitriol may be detected in the fetal circulation. Mild hypercalcemia has been reported in a newborn following maternal use of calcitriol during pregnancy. Adverse effects on fetal development were not observed with use of calcitriol during pregnancy in patients (N=9) with pseudovitamin D-dependent rickets. Doses were adjusted every 4 weeks to keep calcium concentrations within normal limits (Edouard 2011). If calcitriol is used for the management of hypoparathyroidism in pregnancy, dose adjustments may be needed as pregnancy progresses and again following delivery. Vitamin D and calcium levels should be monitored closely and kept in the lower normal range (Callies 1998).</p></div>
<div class="block brc drugH1Div" id="F28561761"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Low levels of calcitriol are found in breast milk (~2 pg/mL)</p></div>
<div class="block dic drugH1Div" id="F28561800"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">May be taken without regard to food. Give with meals to reduce GI problems. Adequate calcium intake should be maintained during therapy; dietary phosphorous may need to be restricted.</p></div>
<div class="block mop drugH1Div" id="F28561806"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Secondary hyperparathyroidism (patients with CKD):</b></i>
<b>Note:</b> The frequency of serum calcium, phosphate, and parathyroid hormone (PTH) measurements may be dependent upon the presence and magnitude of abnormalities, the rate of progression of chronic kidney disease (CKD), and the use of treatments for chronic kidney disease-mineral and bone disorder (KDIGO 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>During therapy initiation and dosage adjustments:</b> Frequent monitoring of serum calcium and phosphate levels (eg, at least twice weekly) is recommended (manufacturer’s labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>KDIGO guidelines (2017): Note:</b> During treatment or when biochemical abnormalities are identified more frequent monitoring may be reasonable.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CKD stage G3a to G3b:</i> Serum calcium and phosphate: Every 6 to 12 months; PTH: Frequency based on baseline level and progression of CKD; alkaline phosphatase.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CKD stage G4:</i> Serum calcium and phosphate: Every 3 to 6 months; PTH: Every 6 to 12 months; alkaline phosphatase every 12 months or more frequently in the presence of elevated PTH.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CKD stage G5 and G5D:</i> Serum calcium and phosphate: Every 1 to 3 months; PTH: Every 3 to 6 months; alkaline phosphatase every 12 months or more frequently in the presence of elevated PTH.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Hypoparathyroidism:</i> Note:</b> Frequency of measurement is dependent upon on how stable a patient is to a given dosage regimen with more frequent measurements (eg, weekly) required initially during dosage titration. Once hypoparathyroidism is well controlled, monitoring may be required on a yearly or twice-yearly basis (ES [Brandi 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">Serum calcium, phosphate, and magnesium; renal function (ie, 24-hour urinary calcium and creatinine, blood urea nitrogen [BUN], measured CrCl or estimated glomerular filtration rate [eGFR]); renal imaging (every 5 years in asymptomatic patients with a history of renal lithiasis or calcinosis or more frequently as indicated); CNS imaging (basal ganglia and other sites of calcification), ophthalmologic exam, and/or BMD as indicated (ES [Brandi 2016]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Hypophosphatemia, X-linked (off-label use):</b></i>Serum calcium, phosphorous, PTH, alkaline phosphatase (ALP) (elevation in ALP of bone-origin may indicate extensive osteomalacia), and creatinine and 24-hour urinary calcium and creatinine (4 to 6 weeks after initiation of therapy, 6 to 8 weeks after satisfactory biochemical response is achieved and then every 3 to 4 months for the first year and every 6 to 9 months thereafter (Carpenter 2011).</p></div>
<div class="block rer drugH1Div" id="F28561782"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Due to the complexity and interdependency of the laboratory parameters used for therapeutic decisions in chronic kidney disease-mineral and bone disorder (CKD-MBD) patients, serial assessments of phosphate, calcium, and parathyroid hormone (PTH) levels should be considered together (KDIGO 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Calcium (total): Adults: Normal range: 8.6 to 10.2 mg/dL (SI: 2.2 to 2.6 mmol/L). Avoid hypercalcemia for chronic kidney disease (CKD) stages G3a to G5D (KDIGO 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Phosphorus: 3 to 4.5 mg/dL (SI: 1 to 1.5 mmol/L). Lower elevated phosphorus levels toward the normal range for CKD stages G3a to G5D (KDIGO 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">PTH:</p>
<p style="text-indent:-2em;margin-left:6em;">CKD stage G3a to G5: Optimal PTH level is unknown; evaluate patients with progressively elevated intact PTH levels or if levels are consistently above the normal range (assay-dependent) (KDIGO 2017)</p>
<p style="text-indent:-2em;margin-left:6em;">Dialysis patients: Maintain intact parathyroid hormone (iPTH) within 2 to 9 times the upper limit of normal for the assay used (KDIGO 2017)</p></div>
<div class="block pha drugH1Div" id="F28561780"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Calcitriol, the active form of vitamin D (1,25 hydroxyvitamin D<sub>3</sub>), binds to and activates the vitamin D receptor in kidney, parathyroid gland, intestine, and bone, stimulating intestinal calcium transport and absorption. It reduces parathyroid hormone (PTH) levels and improves calcium and phosphate homeostasis by stimulating bone resorption of calcium and increasing renal tubular reabsorption of calcium. Decreased renal conversion of vitamin D to its primary active metabolite (1,25 hydroxyvitamin D) in chronic renal failure leads to reduced activation of vitamin D receptor, which subsequently removes inhibitory suppression of parathyroid hormone (PTH) release; increased serum PTH (secondary hyperparathyroidism) reduces calcium excretion and enhances bone resorption.</p></div>
<div class="block phk drugH1Div" id="F28561783"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Oral: 2 hours; maximum effect: 10 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: Oral, IV: 3 to 5 days </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Oral: Rapid </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 99.9% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Primarily to calcitroic acid and a lactone metabolite</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Children 1.8-16 years undergoing peritoneal dialysis: 27.4 hours; Healthy adults: 5 to 8 hours; Hemodialysis: 16 to 22 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: Oral: 3 to 6 hours; Hemodialysis: 8 to 12 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces (27%); urine (7%, unchanged in 24 hours)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Clearance: Children 1.8 to 16 years undergoing peritoneal dialysis: 15.3 mL/hour/kg </p></div>
<div class="block phksp drugH1Div" id="F51154232"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: The half-life is increased by at least 2-fold.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F46329904"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Rocaltrol</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Calcitriol Purissimus | Raquiferol d3 | Raquitriol | Rexamat | Subical cb</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Bocatriol | Calcijex | Rocaltrol</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo calcitriol | Calcijex | Calciprox | Calcitriol an | Calcitriol Ga | Calcitriol PS | Calcitriol sandoz | Calitrol | Citrihexal | Kosteo | Rocaltrol | Sical | Sitriol</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Calcijex | Calcitrol licap | Caloren | Colitrol | Dicaltrol | Encatrol | Improcal | Liquical | Lucent | Ostriol | Promocal | Rocaltrol</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Rocaltrol</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Osteo d | Rocaltrol</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Calcijex | Ostriol | Rocaltrol | Sigmatriol</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Calcitriol Salmon Pharma | Renatriol | Rocaltrol</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Ostriol</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Rocaltrol</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Gai chun | Gai san chun | Hai ka luo | Hicalol | Macolol | Rocaltrol</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Calcijex | Citriopor | Decal | Macalol | Rocaltrol</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Calcijex | Osteod | Rocaltrol</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Bocatriol | Calcitriol gry | Calcitriol Hexal | Calcitriol kyramed | Calcitriol nefro | Decostriol | Osteotriol | Renatriol | Rocaltrol</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Rocaltrol</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Calcitriol nifa | Calsolid | Fortiol | Rocaltrol</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Rocaltrol</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Calcijex | Calcitriol Kern pharma | Calcitriol Teva | Rocaltrol</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Rocaltrol</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Rocaltrol</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Calcijex | Rocaltrol</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Calcitrol | Ostitriol</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Calcijex | Osteodiol | Rocaltrol</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Rocaltrol</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Calcijex | Osteo d | Rocaltrol</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Calcijex | Calcit | Ecatrol | Kolkatriol | Oscal | Osteofem | Ostovel | Ostriol | Rocaltrol</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Rocaltrol</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Calcijex</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">ActiveD | Aristrol | Auxitrol | Bio-d3 | Calcibest | Calcijet | Calosto | Caltive | Caltrol | Celcotriol | Celol | Kindtrol | Laretol | Neph Celol | Nephcal | Nephtrol | Ostriol | Pt Press | Rocaltrol | Rolsical | Septriol | Velvetrol</span>;</li>
<li>
<span class="countryCode">(IR)</span> <span class="country">Iran, Islamic Republic of</span><span class="countrySeparator">: </span><span class="drugName">Zavitrol</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Calcijex | Calcitriolo | Calcitriolo doc | Calcitriolo eg | Calcitriolo Hos | Calcitriolo jet | Difix | Rocaltrol | Trikal</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Rocaltrol</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Alcalrole | Alcalrole rakool | Calcitarol | Caldemin | Calmisal | Carciorol | Carciorol hexal | Carciorol taiyo | Cartol | Hipoteriol | Leobinol | Otanol | Poslotle s | Poslotle s mikasa | Restol | Rocalcitol | Rocaltrol | Rocaltrol chugai | Rocaltrol kyorin | Siopricart | Ticocarol | Torusitorin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Meditrol</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Allca | Bacals | Bonky | Cabone | Calaben | Calci | Calcibon | Calcibone | Calcijex | Calcio | Calcitarol | Calcitin | Calinol | Calio | Callibin | Calribon | Caltriol | Caltron | Calvict | Calvicte | Cicarol | Kaorin | Neobon | Poscal | Rocaltrol | Rocical | Roical | Tariol | Trical</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Rocaltrol</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Rocaltrol</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Osteotriol | Rocaltrol</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Altrol | Calcitriol bruluart | Calcitriol Loeffler | Calcitrol | Decatriol | Ercatriv m | Felipgel f | Geldex | Gyneamsa | Lemytriol | Nafartol | Rocaltrol | Roctrol | Tirocal</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Bonky | Calcijex | Decostriol | Rocaltrol | Roical</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Meditrol</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Calcijex | Rocaltrol</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Rocaltrol</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Calcitriol AFT | Rocaltrol</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Ciocal d | Decal | Rocaltrol | Triocalcit</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Amcitrol | Calcijex | Caltri | Renatrol | Rocaltrol | Vitadol</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Calciol | Calibin | Caltriol | Rocaltrol</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Calcijex | Calcitriol gry | Decostriol | Kalcytriol | Rocaltrol</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Calcijex | Rocaltrol</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Calcijex | Rocaltrol</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Caleobrol | Geldex | Ostriol | Rocaltrol</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Rocaltrol</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Osteo d</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Osteotriol | Rocaltrol</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Rocaltrol</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Bocatriol | Rocaltrol</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Calcijex | Meditrol | Rasputin | Rocaltrol | Roical</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Calcijex | Osteo d | Rocaltrol</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Calcijex | Osteo d | Rocaltrol</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Cacare | Decostriol | Osteod | Rocaltrol</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Cajex | Calcijex | Calderol | Caltrioject | Osteo d | Ostriol | Qalyviz | Rocaltrol | Teory</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Alcalrole | Cacare | Calcijex | Caltsue | Hicalol | Hicatrol | Macalol | Rocaltrol | U CA</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Phorcal</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Meditrol</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Calcitriol Purissimus | Dexiven | Rocaltrol</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Rocaltrol</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Borabone | Masak</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Rocaltrol</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Aluminum.1">
<a name="Aluminum.1"></a>Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Fed Regist</i>. 2002;67(244):77792-77793.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20339510">
<a name="20339510"></a>Amaral JM, Abrams S, Karaviti L, McKay SV. Effects of 1,25-dihydroxycholecalciferol on recovery and resolution of late transient neonatal hypocalcemia. <i>Int J Pediatr Endocrinol</i>. 2010;2010:409670. doi:10.1155/2010/409670<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitriol-systemic-drug-information/abstract-text/20339510/pubmed" id="20339510" target="_blank">20339510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9335388">
<a name="9335388"></a>Ash SR, Gloeckner PJ, Barnett SL. Lack of removal of calcitriol during hemodialysis procedures.<i> J Am Soc Nephrol.</i> 1997;8(10):1587-1591. doi:10.1681/ASN.V8101587<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitriol-systemic-drug-information/abstract-text/9335388/pubmed" id="9335388" target="_blank">9335388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12358640">
<a name="12358640"></a>Bailie GR, Johnson CA. Comparative review of the pharmacokinetics of vitamin D analogues. <i>Semin Dial.</i> 2002;15(5):352-357. doi:10.1046/j.1525139x.2002.00086.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitriol-systemic-drug-information/abstract-text/12358640/pubmed" id="12358640" target="_blank">12358640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33245331">
<a name="33245331"></a>Bakkaloglu SA, Bacchetta J, Lalayiannis AD, et al. Bone evaluation in paediatric chronic kidney disease: clinical practice points from the European Society for Paediatric Nephrology CKD-MBD and Dialysis working groups and CKD-MBD working group of the ERA-EDTA. <i>Nephrol Dial Transplant</i>. 2021;36(3):413-425. doi:10.1093/ndt/gfaa210<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitriol-systemic-drug-information/abstract-text/33245331/pubmed" id="33245331" target="_blank">33245331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26943719">
<a name="26943719"></a>Brandi ML, Bilezikian JP, Shoback D, et al. Management of hypoparathyroidism: summary statement and guidelines. <i>J Clin Endocrinol Metab</i>. 2016;101(6):2273-2283. doi:10.1210/jc.2015-3907<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitriol-systemic-drug-information/abstract-text/26943719/pubmed" id="26943719" target="_blank">26943719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AbbVie.1">
<a name="AbbVie.1"></a>Calcijex (injection solution) [prescribing information]. North Chicago, IL: AbbVie Inc; April 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Akorn.1">
<a name="Akorn.1"></a>Calcitriol injection [prescribing information]. Lake Forest, IL: Akorn Inc; June 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Teva.1">
<a name="Teva.1"></a>Calcitriol (oral capsule) [prescribing information]. Sellersville, PA: Teva Pharmaceuticals; January 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9758437">
<a name="9758437"></a>Callies F, Arlt W, Scholz HJ, et al. Management of hypoparathyroidism during pregnancy -- report of twelve cases. <i>Eur J Endocrinol.</i> 1998;139(3):284-289.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitriol-systemic-drug-information/abstract-text/9758437/pubmed" id="9758437" target="_blank">9758437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21538511">
<a name="21538511"></a>Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician's guide to X-linked hypophosphatemia [published correction appears in: <i>J Bone Miner Res</i>. 2015;30(2):394]. <i>J Bone Miner Res</i>. 2011;26(7):1381-1388. doi:10.1002/jbmr.340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitriol-systemic-drug-information/abstract-text/21538511/pubmed" id="21538511" target="_blank">21538511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19775201">
<a name="19775201"></a>Cauley JA, Parimi N, Ensrud KE, et al. Serum 25-hydroxyvitamin D and the risk of hip and nonspine fractures in older men. <i>J Bone Miner Res</i>. 2010;25(3):545-553.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitriol-systemic-drug-information/abstract-text/19775201/pubmed" id="19775201" target="_blank">19775201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-650355">
<a name="650355"></a>Chan GM, Tsang RC, Chen IW, DeLuca HF, Steichen JJ. The effect of 1,25(OH)2 vitamin D3 supplementation in premature infants. <i>J Pediatr</i>. 1978;93(1):91-96. doi:10.1016/s0022-3476(78)80613-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitriol-systemic-drug-information/abstract-text/650355/pubmed" id="650355" target="_blank">650355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29633734">
<a name="29633734"></a>Di Maio S, Soliman AT, De Sanctis V, Kattamis CC. Current treatment of hypoparathyroidism: Theory versus reality waiting guidelines for children and adolescents. <i>Acta Biomed</i>. 2018;89(1):122-131. doi:10.23750/abm.v89i1.7118<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitriol-systemic-drug-information/abstract-text/29633734/pubmed" id="29633734" target="_blank">29633734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Doyle.1">
<a name="Doyle.1"></a>Doyle DA. Hypoparathyroidism. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Saunders Elsevier; 2020:chap. 589.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20926527">
<a name="20926527"></a>Edouard T, Alos N, Chabot G, et al. Short- and long-term outcome of patients with pseudo-vitamin D deficiency rickets treated with calcitriol. <i>J Clin Endocrinol Metab.</i> 2011;96(1):82-89. doi:10.1210/jc.2010-1340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitriol-systemic-drug-information/abstract-text/20926527/pubmed" id="20926527" target="_blank">20926527</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31042826">
<a name="31042826"></a>Gafni RI, Collins MT. Hypoparathyroidism. <i>N Engl J Med</i>. 2019;380(18):1738-1747. doi:10.1056/NEJMcp1800213<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitriol-systemic-drug-information/abstract-text/31042826/pubmed" id="31042826" target="_blank">31042826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25990370">
<a name="25990370"></a>Gafni RI, Guthrie LC, Kelly MH, et al. Transient increased calcium and calcitriol requirements after discontinuation of human synthetic parathyroid hormone 1-34 (hPTH 1-34) replacement therapy in hypoparathyroidism. <i>J Bone Miner Res</i>. 2015;30(11):2112-2118. doi:10.1002/jbmr.2555<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitriol-systemic-drug-information/abstract-text/25990370/pubmed" id="25990370" target="_blank">25990370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goltzman.1">
<a name="Goltzman.1"></a>Goltzman D. Treatment of hypocalcemia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 9, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Greenbaum.1">
<a name="Greenbaum.1"></a>Greenbaum LA. Vitamin D deficiency (rickets) and excess. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Saunders Elsevier; 2020:chap. 64.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hutchison.1">
<a name="Hutchison.1"></a>Hutchison LC, Sleeper RB. Gastrointestinal disorders and nutrition. In: <i>Fundamentals of Geriatric Pharmacotherapy. </i>Hutchison LC, Sleeper RB, eds. ASHP Publications; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IOM.1">
<a name="IOM.1"></a>Institute of Medicine (IOM). <i>Dietary Reference Intakes for Calcium and Vitamin D</i>. The National Academies Press; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28941764">
<a name="28941764"></a>Isakova T, Nickolas TL, Denburg M, et al. KDOQI US commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). <i>Am J Kidney Dis</i>. 2017;70(6):737-751. doi:10.1053/j.ajkd.2017.07.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitriol-systemic-drug-information/abstract-text/28941764/pubmed" id="28941764" target="_blank">28941764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20737250">
<a name="20737250"></a>Jain A, Agarwal R, Sankar MJ, Deorari A, Paul VK. Hypocalcemia in the newborn. <i>Indian J Pediatr</i>. 2010;77(10):1123-1128. doi:10.1007/s12098-010-0176-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitriol-systemic-drug-information/abstract-text/20737250/pubmed" id="20737250" target="_blank">20737250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDOQI.1">
<a name="KDOQI.1"></a>K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. <i>Am J Kidney Dis</i>. 2005;46(4)(suppl 1):S1-S121.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30675420">
<a name="30675420"></a>Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) [published correction appears in: <i>Kidney Int Suppl (2011).</i> 2017;7(3):e1]. <i>Kidney Int Suppl (2011).</i> 2017;7(1):1-59. doi:10.1016/j.kisu.2017.04.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitriol-systemic-drug-information/abstract-text/30675420/pubmed" id="30675420" target="_blank">30675420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10227320">
<a name="10227320"></a>LeBoff MS, Kohlmeier L, Hurwitz S, Franklin J, Wright J, Glowacki J. Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. <i>JAMA</i>. 1999;281(16):1505-1511.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitriol-systemic-drug-information/abstract-text/10227320/pubmed" id="10227320" target="_blank">10227320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3555761">
<a name="3555761"></a>Letsou AP, Price LS. Health, aging, and nutrition. An overview. <i>Clin Geriatr Med</i>. 1987;3(2):253-260.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitriol-systemic-drug-information/abstract-text/3555761/pubmed" id="3555761" target="_blank">3555761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oconnell.1">
<a name="Oconnell.1"></a>O’Connell MB, Fritsch MA. Musculoskeletal and connective tissue disorders. Hutchison LC, Sleeper RB. Gastrointestinal disorders and nutrition. In: <i>Fundamentals of Geriatric Pharmacotherapy. </i>Hutchison LC, Sleeper RB, eds. ASHP Publications; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21158219">
<a name="21158219"></a>Patra S, Singh V, Pemde HK, Chandra J. Case series of neonatal hypocalcemia due to pseudohypoparathyroidism. <i>J Pediatr Endocrinol Metab</i>. 2010;23(10):1073-1075. doi:10.1515/jpem.2010.169<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitriol-systemic-drug-information/abstract-text/21158219/pubmed" id="21158219" target="_blank">21158219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Quarles.1">
<a name="Quarles.1"></a>Quarles LD, Berkoben M. Management of secondary hyperparathyroidism in adult dialysis patients. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 31, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Quarles.2">
<a name="Quarles.2"></a>Quarles LD, Berkoben M. Management of secondary hyperparathyroidism in adult nondialysis patients with chronic kidney disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 31, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Validus.1">
<a name="Validus.1"></a>Rocaltrol (calcitriol) [prescribing information]. Parsippany, NJ: Validus Pharmaceuticals; May 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Searchlight.1">
<a name="Searchlight.1"></a>Rocaltrol (calcitriol) [product monograph]. Montreal, Quebec, Canada: Searchlight Pharma Inc; January 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Root.1">
<a name="Root.1"></a>Root AW. Disorders of minderal metabolism II. Abnormalities of mineral homeostasis in the newborn, infant, child, and adolescent. In: Sperling MA, ed. <i>Pediatric Endocrinology</i>. 5th ed. Elsevier; 2020:chap. 20.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7070879">
<a name="7070879"></a>Salle BL, David L, Glorieux FH, Delvin E, Senterre J, Renaud H. Early oral administration of vitamin D and its metabolites in premature neonates. Effect on mineral homeostasis. <i>Pediatr Res</i>. 1982;16(1):75-78. doi:10.1203/00006450-198201001-00015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitriol-systemic-drug-information/abstract-text/7070879/pubmed" id="7070879" target="_blank">7070879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22285224">
<a name="22285224"></a>Shoben AB, Levin G, de Boer IH, et al. Variation in oral calcitriol response in patients with stages 3-4 CKD. <i>Am J Kidney Dis</i>. 2012;59(5):645-52. doi:10.1053/j.ajkd.2011.11.041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitriol-systemic-drug-information/abstract-text/22285224/pubmed" id="22285224" target="_blank">22285224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22614771">
<a name="22614771"></a>Thomas TC, Smith JM, White PC, Adhikari S. Transient neonatal hypocalcemia: presentation and outcomes. <i>Pediatrics</i>. 2012;129(6):e1461-e1467. doi:10.1542/peds.2011-2659<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitriol-systemic-drug-information/abstract-text/22614771/pubmed" id="22614771" target="_blank">22614771</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 107353 Version 212.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
